Highest-materiality recent filing
MiniMed holders re-elect four Class I directors, ratify PwC, back annual say-on-pay votes
All four director nominees elected at Oct 9, 2026 annual meeting: Kevin E. Lofton (273,936,720 for), David J. Endicott (275,525,168), D. Keith Grossman (273,943,472) and Tim A. Wicks (273,946,011).
MiniMed Q1 FY27 net sales $843M +16.6%; raises FY27 organic growth to ~10.5%
Net sales $843M, +16.6% as reported, +15.8% organic; U.S. +13.1% to $240M, international +18.1% to $603M.
MiniMed General Counsel Courtney Nelson Wills resigns effective Sept 25, 2026
Courtney Nelson Wills, SVP, General Counsel and Corporate Secretary, notified MiniMed of resignation on July 30, 2026.
MiniMed expands board to 11; appoints David Endicott (Alcon CEO) and Linnea Burman (Medtronic SVP)
Board increased from 9 to 11; appointments effective June 29, 2026.
MiniMed Q4 net sales $837M (+16% as reported); FY27 organic growth guidance ~10%
Q4 net sales $837M (+15.6% as reported, +8.7% organic); International $599M (+22.4% as reported, +12.2% organic).
MiniMed director Brett Wall resigns; Scott Cundy appointed effective July 3, 2026
Brett Wall (class II director) resigns effective July 3, 2026; no disagreement with management or board.
MiniMed parent Medtronic discloses unauthorized third-party data access; MiniMed IT not compromised
Medtronic reported an unauthorized third party accessed data in certain IT systems on April 24, 2026.
MiniMed adopts new executive severance plans: 2x pay on non-CIC termination, 3x on CIC
Severance Plan for Executives provides lump sum equal to 2x base salary plus target annual bonus, plus 24 months COBRA on non-CIC termination.
MiniMed Flex insulin pump receives FDA clearance months early; $157M charge expected in Q4 FY2026
FDA cleared MiniMed Flex insulin pump several months earlier than expected, enabling earlier commercialization.
MiniMed Group completes IPO, raises ~$560M; Medtronic retains 90% ownership
IPO of 28M shares at $20/share; net proceeds ~$560M; $309M retained for corporate purposes, excess repays Medtronic intercompany debt.
On June 25, 2026, the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) increased the size of the Board from nine to 11 and appointed David Endicott and Linnea Burman to serve as a directors of the Board to fill the resulting vacancies, effective June 29, 2026.
On June 25, 2026, the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) increased the size of the Board from nine to 11 and appointed David Endicott and Linnea Burman to serve as a directors of the Board to fill the resulting vacancies, effective June 29, 2026.
On May 18, 2026, Scott Cundy was appointed to serve as a director of the Board, effective July 3, 2026, to fill the vacancy resulting from Mr. Wall’s departure.
On May 17, 2026, Brett Wall, a class II director of the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) and member of the Board’s Nominating and Corporate Governance Committee, notified the Board that he will resign from the Board effective July 3, 2026.
Max materiality 1.00 · Median 0.53 · Most common event other_material